Pages that link to "Q42245850"
Jump to navigation
Jump to search
The following pages link to Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients (Q42245850):
Displaying 50 items.
- Long-term follow-up of patients with recurrent unexplained syncope evaluated by electrophysiologic testing (Q33172694) (← links)
- Sudden cardiac death--a perspective (Q33581362) (← links)
- Hepatotoxicity associated with amiodarone therapy (Q34497962) (← links)
- Amiodarone: the experience of the past decade (Q34996861) (← links)
- Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias (Q35313411) (← links)
- Class III drugs: their effects on arrhythmias and on the QT interval (Q35994626) (← links)
- Amiodarone pneumonitis: three further cases with a review of published reports (Q36134292) (← links)
- Amiodarone in Long Term Prophylaxis (Q36660391) (← links)
- Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance (Q36663794) (← links)
- Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction (Q36828553) (← links)
- Pharmacology and pharmacokinetics of amiodarone (Q36832174) (← links)
- Amiodarone Therapy Guided by Electrophysiologic Testing: An Update (Q36832205) (← links)
- Uses and limitations of electrophysiology studies for the selection of antiarrhythmic therapy (Q38160476) (← links)
- Amiodarone: value of programmed electrical stimulation and Holter monitoring (Q38163269) (← links)
- Electrophysiologic-electropharmacologic testing in patients with ventricular arrhythmias (Q38186779) (← links)
- Long-term efficacy and toxicity of high- and low-dose amiodarone regimens (Q38652012) (← links)
- The role of electrophysiologic testing in the selection of amiodarone therapy (Q38652020) (← links)
- Pharmacokinetic drug interactions with amiodarone (Q38688250) (← links)
- A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs? (Q38742583) (← links)
- Amiodarone in the management of cardiac arrhythmias: current concepts (Q39631851) (← links)
- New antiarrhythmic drugs (Q39642164) (← links)
- Cardiac electrophysiologic testing: its role in the selection of antiarrhythmic drug regimens for supraventricular and ventricular arrhythmias (Q39821044) (← links)
- Amiodarone: individualizing dosage with serum concentrations (Q40108610) (← links)
- Ventricular Tachycardia-1983 (Q40109375) (← links)
- Serious adverse effects of amiodarones (Q40172313) (← links)
- Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects (Q40172905) (← links)
- Clinical pharmacokinetics of amiodarone (Q40174713) (← links)
- Clinical pharmacology of amiodarone (Q40181664) (← links)
- Clinical use and pharmacology of amiodarone (Q40190296) (← links)
- Electrophysiologic testing: predictive of amiodarone efficacy in recurrent sustained ventricular tachycardia? (Q40484997) (← links)
- Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias (Q40601626) (← links)
- New antiarrhythmic drugs in pediatric use: amiodarone (Q40681386) (← links)
- Effect of amiodarone on retrograde conduction and refractoriness of the His-Purkinje system in man. (Q41306354) (← links)
- Worsening of ventricular tachycardia by amiodarone (Q42214578) (← links)
- Probable early acute hepatitis with parenteral amiodarone (Q42220918) (← links)
- Asystole during treatment with amiodarone in a patient with persistent atrial tachycardia (Q42225041) (← links)
- Fatal hepatic failure and encephalopathy associated with amiodarone therapy (Q42229697) (← links)
- Interaction of amiodarone and diphenylhydantoin (Q42250634) (← links)
- Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias (Q42254976) (← links)
- Amiodarone-induced intra-His block (Q42256439) (← links)
- Comparison of survival of amiodarone-treated patients with coronary artery disease and malignant ventricular arrhythmias with that of a control group with coronary artery disease (Q44415897) (← links)
- Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment (Q44490303) (← links)
- Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation? (Q45080745) (← links)
- Selecting therapy for sustained ventricular tachycardias: importance of the sensitivity and specificity of programmed electrical stimulation for predicting arrhythmia recurrences (Q45360612) (← links)
- Mortality benefit of implantable cardioverter-defibrillator therapy in patients with persistent malignant ventricular arrhythmias despite amiodarone treatment. (Q45957265) (← links)
- New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. (Q51782188) (← links)
- Amiodarone. Haemodynamic profile during intravenous administration and effect on pacing-induced ischaemia in man. (Q53757545) (← links)
- Hemodynamic effects of intravenous amiodarone. (Q54469265) (← links)
- Drug-Induced Interstitial Lung Disease: A Systematic Review (Q57463653) (← links)
- Programmed stimulation in the evaluation of life-threatening or potentially life-threatening ventricular arrhythmias (Q67269578) (← links)